Natera Beat Consensus Estimates

Natera (NTRA) reported a loss of $0.50 per share on revenue of $501.83 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.59 per share on revenue of $443.34 million. The company beat consensus estimates by 15.25% while revenue grew 36.46% on a year-over-year basis.

The company said it expects 2025 revenue of $1.94 billion to $2.02 billion. The company's previous guidance was revenue of $1.87 million to $1.95 million and the current consensus revenue estimate is $1.92 billion for the year ending December 31, 2025.

Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw.